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RABBIT SYNDROME - AN UNCOMMON 
SIDE-EFFECT OF NEUROLEPTICS 
Sir, 
Gada (1997) while reporting case of 
Rabbit Syndrome describes it as first in Indian 
literature. But to my knowledge at least two 
more cases have been reported earlier. 
Gangadhar et al. (1981) and I myself (Jain, 
1993) have reported these cases in Journals 
none other then the official publications of I.P.S. 
itself. 
Gangadhar et al. (1981) reported this 
movement disorder in his patient while he was 
given a high potency neuroleptic in injectable 
form in addition to antipsychotics he earlier 
received. They also noted that there was patchy 
disappearance of movement during stage I of 
NREM sleep. 
My case suffered with this movement 
disorder when she was admitted for her manic 
episode and received a high potency 
neuroleptic in injectable form. This happened 
just after a week of receiving the injectable 
preparation. She was receiving no 
anticholinergic medication as no E.P.S. was 
obvious. 
This case differed from previously 
reported cases in two ways- (i) she was 
suffering from bipolar affective disorder while 
earlier reported cases were schizophrenics; (ii) 
the duration of exposure to neuroleptics was 
quite brief in this case while this syndrome is 
known to occur only after prolonged use. 
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RABBIT SYNDROME 
Sir. 
With reference to Manilal Gada's 
article "Rabbit syndrome-an uncommon side 
effect of neuroleptics" published in this journal 
(vol 39, No 2,1997). I have to inform you, that 
while the report is interesting, author's 
impression that this is perhaps the first case 
reported from India is not correct. 
We have published a case report on 
"Rabbit syndrome- a rare complication of long 
term neuroleptic medication" (Deshmukh et al., 
1990). 
The syndrome is indeed rare, and I have 
not come across another case. 
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PSYCHOTROPIC DRUG SALES IN 
WARANGAL 
Sir. 
I thank Andrade for his comments (UP, 
letters to editor, April, 1997) on my article about 
psychotropic drug sales in Warangal. 
His presumptions that higher utilization 
of drug may reflect the prevalence of the 
disorder for which the drug is prescribed, higher 
utilization of a drug may reflect the range of 
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indications for which the drug is indicated and 
the formula based on average dose does not 
stand to practical reality. It is scientific but drug 
prescribing practices are far from scientific. It 
was and is the observation of the author that all 
the diagnoses noted on the prescriptions are 
either depression and/or AN. Patients after a 
single visit, use the same on and off for 
prolonged periods. Under these circumstances 
coming to any other conclusion based on one's 
own presumptions is hazardous. Ground 
realities are far different and ignoring them will 
lead to confined conclusions. 
A thorough reading of the article will 
show newer antipsychotics, which are costly, 
had less sales so the question of costly drugs 
pushing up the sales did not arise. Further 
simple computation of data presented shows 
that the order of sales in Rs., is in agreement 
with all India sales-tranquiiiizers, including 
alprazolam, Rs. 19.38 lacs, antidepressants, in-
cluding fluoxetine, 16.35 lacs and 
antipsychotics Rs. 8.27 lacs. This indicates that 
prescribing practices are same in other parts 
of the country. 
I thank Chittaranjan Andrade for 
pointing an alternative interpretation of the data 
presented and for the pure scientific value of it. 
P. GOPALA SARMA, Prof. & Head, Department 
of Psychiatry, Warangal 506 007. 
DRUG PROPHYLAXIS OF 
SCHIZOPHRENIA ? 
Sir, 
We wish to draw attention of the 
readers of your prestigious journal to the 
aspect of drug prevention of schizophrenia. This 
becomes more relevant as the market for newer 
antipsychotic drugs especially atypical ones 
may expand in view of ideas expressed at 
recently concluded 6th world Congress of 
Biological Psychiatry in Nice. According to Prof. 
Patrick McGorry of Melbourne University, 
prophylactic or preventive treatment of pre 
schizophrenics with neuroleptics could become 
an important area. He says 43% of individuals 
with a certain cluster of risk factors (genetic 
loading, psychosocial dysfunction and paranoia) 
may become psychotic within 12 months (Prod-
ucts, 1997). The so called prodromal symptoms 
may develop many years before fullfledged 
positive symptoms such as delusions and hal-
lucinations appear. These combined with lack 
of motivation, initiative and decreased emo-
tional responsiveness to external stimuli in 
surroundings resemble more closely to 
negative symptoms. These features have also 
been described in simple schizophrenia. Do 
negative symptoms precede positive symptoms 
? This is another question worth investigation. 
But in this context prevention of schizophrenia 
with atypical neuroleptics, though controversial, 
could become pertinent. Eli Lilly in 
collaboration with National Institute of Mental 
Health have planned to initiate treatment with 
olanzapine to delay or even prevent the onset 
of disease. However, the continuing advance 
in understanding of genetics of the disease 
would help in identification of persons at rela-
tive risk with greater accuracy. But in our view 
such prepositions where neuroleptic drugs shall 
be used over a prolonged period there are two 
major limitations-first precipitation of 
psychosis and second appearance of side 
effects. 
There is evidence that increased 
dopamine (DA) receptor binding sites in the 
neostriatum and this alongwith DA 
supersensitivity due to chronic receptor 
blockade are responsible for tardive dyskinesia 
(Burt et al., 1977). Similarly after chronic 
exposure to neuroleptics, there may be an 
increase in DA receptor binding sites in 
mesolimbic area as well. This could result in 
the appearance of psychotic symptoms when 
neuroleptic medication is withdrawn, decreased 
or even held at constant dosage for a certain 
period of time. There is an evidence that 
psychosis can develop in patients suffering from 
nonpsychotic disorder treated with neuroleptic 
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